How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

102 results for

Hypersomnolence Causes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Hypersomnolence Causes

Hypersomnolence Causes Hypersomnolence Causes Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Hypersomnolence Causes Hypersomnolence (...) Causes Aka: Hypersomnolence Causes From Related Chapters II. Causes: Sleep deprivation Most common cause of excessive deprivation adversely affects neurobehavioral functioning after 1 night and is cummulative III. Causes: Neurologic ( : Up to 0.18% of general population) Idiopathic daytime (accounts for 10% of suspected cases) Neurologic Injury or disorder (CVA) Myoclonic Movements Disorder IV. Causes: Psychiatric and Lifestyle Habits Poor Circadian Rhythm abnormalities (nightshift changes, ) V

2018 FP Notebook

2. Car Crashes and Central Disorders of Hypersomnolence: A French Study (PubMed)

Car Crashes and Central Disorders of Hypersomnolence: A French Study Drowsiness compromises driving ability by reducing alertness and attentiveness, and delayed reaction times. Sleep-related car crashes account for a considerable proportion of accident at the wheel. Narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) are rare central disorders of hypersomnolence, the most severe causes of sleepiness thus being potential dangerous conditions for both personal (...) and public safety with increasing scientific, social, and political attention. Our main objective was to assess the frequency of recent car crashes in a large cohort of patients affected with well-defined central disorders of hypersomnolence versus subjects from the general population.We performed a cross-sectional study in French reference centres for rare hypersomnia diseases and included 527 patients and 781 healthy subjects. All participants included needed to have a driving license, information

Full Text available with Trip Pro

2015 PloS one

3. Hypersomnolence Causes

Hypersomnolence Causes Hypersomnolence Causes Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Hypersomnolence Causes Hypersomnolence (...) Causes Aka: Hypersomnolence Causes From Related Chapters II. Causes: Sleep deprivation Most common cause of excessive deprivation adversely affects neurobehavioral functioning after 1 night and is cummulative III. Causes: Neurologic ( : Up to 0.18% of general population) Idiopathic daytime (accounts for 10% of suspected cases) Neurologic Injury or disorder (CVA) Myoclonic Movements Disorder IV. Causes: Psychiatric and Lifestyle Habits Poor Circadian Rhythm abnormalities (nightshift changes, ) V

2015 FP Notebook

4. Ambulatory Sleep Study for diagnosing obstructive sleep apnoea

hypoventilation; Significant cardiopulmonary disease; Long-term home oxygen therapy; Chronic opiate medication use; Parasomnias (such as REM behavioural disorder); Severe insomnia; Sleep-related movement disorders (such as periodic limp movement disorder); Potential respiratory muscle weakness caused by neuromuscular conditions; History of stroke; Disorders of central hypersomnolence; Nocturnal seizure; and Environmental or personal factors precluding adequate acquisition and data interpretation from HST

2019 Appropriate Care Guides, Agency for Care Effectiveness (Singapore)

5. AIM Clinical Appropriateness Guidelines for Sleep Disorder Management

with idiopathic hypersomnia display difficult morning awakening, sleep drunkenness and constant somnolence. Idiopathic hypersomnia is rarer than narcolepsy and tends to be more resistant to treatment. A diagnosis of idiopathic hypersomnia requires exclusion of other causes of fatigue and hypersomnolence including hypothyroidism, depression, obstructive sleep apnea etc. Multiple sleep latency testing (MSLT): During MSLT the patient is provided several opportunities to nap. Physiologic parameters recorded (...) . Multiple Sleep Latency Testing (MSLT) and Maintenance of Wakefulness Testing (MWT)MSLT and MWT | Copyright © 2019. AIM Specialty Health. All Rights Reserved. 12 Indications for MSLT and/or MWT Initial MSLT and/or MWT is appropriate for suspected narcolepsy when all of the following conditions are met a. Daytime hypersomnolence has been present for at least eight weeks b. The patient has at least one of the following i. Disrupted nocturnal sleep ii. Cataplexy iii. Hallucinations (hypnagogic

2019 AIM Specialty Health

6. Evaluation and Management of Obesity Hypoventilation Syndrome

= obstructive sleep apnea; PAP = positive airway pressure; Sp O 2 = oxygen saturation by pulse oximetry. Introduction Section: OHS is defined by the combination of obesity (body mass index [BMI] ≥ 30 kg/m 2 ), SDB, and awake daytime hypercapnia (awake resting Pa CO 2 ≥ 45 mm Hg at sea level), after excluding other causes for hypoventilation ( , ). OHS is the most severe form of obesity-induced respiratory compromise and leads to serious sequelae, including increased rates of mortality, chronic heart failure (...) of diagnosis? 13. Should PAP therapy (CPAP or NIV) vs. no PAP therapy be used in the management of pulmonary hypertension in patients with OHS? 14. Should a bariatric procedure vs. no bariatric procedure be used as first-line therapy for OHS? For definition of abbreviations, see . The panel selected the following patient-important outcomes: death, quality of life, resolution of daytime hypercapnia and hypoxemia, need for supplemental oxygen, resolution of OHS, daytime hypersomnolence, motor vehicle

Full Text available with Trip Pro

2019 American Thoracic Society

7. Pediatric Home Mechanical Ventilation

caregivers who are knowledgeable not only in ventilator but also tracheostomy management, with tracheostomy-related events being a principal cause of death in these patients. 26 Since adverse events can occur at any time it is generally recommended that a child with a tracheostomy have “24/7” care by an awake, alert, trained caregiver. 27–29 This requires a minimum of 2 caregivers identi?ed who are able and willing to be trained in tracheostomy and ventilator care in order tocare for the child at home

2017 Canadian Thoracic Society

8. Clinical Practice Guideline for Diagnostic Testing for Adult Obstructive Sleep Apnea: An American Academy of Sleep Medicine Clinical Practice Guideline

of therapy. Figure 2 Clinical algorithm for implementation of clinical practice guidelines. The following are good practice statements, the implementation of which is deemed necessary for appropriate and effective diagnosis and management of OSA. Diagnostic testing for OSA should be performed in conjunction with a comprehensive sleep evaluation and adequate follow-up. OSA is one of many medical conditions that may be the cause of sleep complaints and other symptoms. Therefore, diagnostic testing for OSA

2017 American Academy of Sleep Medicine

9. High Blood Pressure in Adults: Guideline For the Prevention, Detection, Evaluation and Management

of Hypertension... e138 3.3. Prevalence of High BP .. e138 3.4. Awareness, Treatment, and Control e139 4.MEASUREMENT OF BP .. e140 4.1. Accurate Measurement of BP in the Of?ce ... e140 4.2. Out-of-Of?ce and Self-Monitoring of BP . e141 4.3. Ambulatory BP Monitoring .. . e142 4.4. Masked and White Coat Hypertension . e143 5.CAUSES OF HYPERTENSION e146 5.1. Genetic Predisposition . e146 5.2. Environmental Risk Factors.. . e146 5.2.1. Overweight and Obesity .. e146 5.2.2. Sodium Intake .. e147 5.2.3. Potassium (...) have been associated with increased CVD risk indepen- dent of SBP and DBP in some studies, SBP (especially) and DBP are prioritized in the present document because of the robust evidence base for these measures in both observational studies and clinical trials and because of their ease of measurement in practice settings (S2.2-8—S2.2-11). 2.3. Population Risk In 2010, high BP was the leading cause of death and disability-adjusted life years worldwide (S2.3-1,S2.3-2).In the United States

2017 American College of Cardiology

10. Sleep Disorder Management Diagnostic & Treatment Guidelines

with idiopathic hypersomnia display difficult morning awakening, sleep drunkenness and constant somnolence. Idiopathic hypersomnia is rarer than narcolepsy and tends to be more resistant to treatment. A diagnosis of idiopathic hypersomnia requires exclusion of other causes of fatigue and hypersomnolence including hypothyroidism, depression, obstructive sleep apnea etc. Multiple sleep latency testing (MSLT): During MSLT the patient is provided several opportunities to nap. Physiologic parameters recorded (...) . Multiple Sleep Latency Testing (MSLT) and Maintenance of Wakefulness Testing (MWT)MSLT and MWT | Copyright © 2017. AIM Specialty Health. All Rights Reserved. 12 Indications for MSLT and/or MWT Initial MSLT and/or MWT is appropriate for suspected narcolepsy when all of the following conditions are met a. Daytime hypersomnolence has been present for at least eight weeks b. The patient has at least one of the following i. Disrupted nocturnal sleep ii. Cataplexy iii. Hallucinations (hypnagogic

2017 AIM Specialty Health

11. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults

Conditions e20 3. Classification of BP e21 3.1. Definition of High BP e21 3.2. Lifetime Risk of Hypertension e22 3.3. Prevalence of High BP e22 3.4. Awareness, Treatment, and Control e22 4. Measurement of BP e23 4.1. Accurate Measurement of BP in the Office e23 4.2. Out-of-Office and Self-Monitoring of BP e24 4.3. Ambulatory BP Monitoring e25 4.4. Masked and White Coat Hypertension e26 5. Causes of Hypertension e28 5.1. Genetic Predisposition e28 5.2. Environmental Risk Factors e28 5.2.1. Overweight (...) 4. BP Measurement Definitions BP Measurement Definition SBP First Korotkoff sound DBP Fifth Korotkoff sound Pulse pressure SBP minus DBP Mean arterial pressure DBP plus one third pulse pressure Mid-BP Sum of SBP and DBP, divided by 2 * See Section 4 for a description of Korotkoff sounds. † Calculation assumes normal heart rate. BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure. 2.3. Population Risk In 2010, high BP was the leading cause of death

2017 American Heart Association

12. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary

. Population Risk 1276 2.4. Coexistence of Hypertension and Related Chronic Conditions 1276 3. Classification of BP 1276 3.1. Definition of High BP 1276 3.2. Lifetime Risk of Hypertension 1277 3.3. Prevalence of High BP 1277 4. Measurement of BP 1277 4.1. Accurate Measurement of BP in the Office 1277 4.2. Out-of-Office and Self-Monitoring of BP 1278 4.3. Masked and White Coat Hypertension 1278 5. Causes of Hypertension 1281 5.1. Secondary Forms of Hypertension 1281 5.1.1. Drugs and Other Substances (...) . † Calculation assumes normal heart rate. BP indicates blood pressure; DBP, diastolic blood pressure; and SBP, systolic blood pressure. 2.3. Population Risk In 2010, high BP was the leading cause of death and disability-adjusted life years worldwide. In the United States, hypertension (see Section 3.1 for definition) accounted for more CVD deaths than any other modifiable CVD risk factor and was second only to cigarette smoking as a preventable cause of death for any reason. In a follow-up study of 23 272 US

2017 American Heart Association

13. Clinical practice guideline for diagnostic testing for adult obstructive sleep apnea: an American Academy of Sleep Medicine clinical practice guideline.

, hypoventilation and sleep related hypoxemia). Examples of these conditions include significant cardiopulmonary disease, potential respiratory muscle weakness due to neuromuscular conditions, history of stroke and chronic opiate medication use. Concern for significant non-respiratory sleep disorder(s) that require evaluation (e.g., disorders of central hypersomnolence, parasomnias, sleep related movement disorders) or interfere with accuracy of HSAT (e.g., severe insomnia). Environmental or personal factors (...) in those with difficulty initiating sleep), and insufficient time to ascertain appropriate continuous positive airway pressure (CPAP) treatment settings. Routinely repeating a polysomnography (PSG) in patients with an initial negative PSG has potential downsides. There is a risk that repeat testing could lead to false positive cases being identified, and unnecessarily treated. In addition, the routine use of a 2-night study protocol would cause inconvenience to the patient, increased utilization

2017 National Guideline Clearinghouse (partial archive)

14. Screening and Diagnosis of Obstructive Sleep Apnea

wakefulness, unrefreshing sleep, fatigue, insomnia, and snoring; the best documented risk factor for OSA is obesity. If other causes have been ruled out, further evaluation may be warranted in patients with daytime sleepiness, states the ACP. The AASM, in contrast, recommends diagnostic testing in uncomplicated adult patients presenting with signs and symptoms that indicate an increased risk of moderate to severe OSA, defined as the presence of excessive daytime sleepiness and at least two (...) of these conditions include significant cardiopulmonary disease, potential respiratory muscle weakness due to neuromuscular conditions, history of stroke and chronic opiate medication use. Concern for significant non-respiratory sleep disorder(s) that require evaluation (e.g., disorders of central hypersomnolence, parasomnias, sleep related movement disorders) or interfere with accuracy of HSAT (e.g., severe insomnia). Environmental or personal factors that preclude the adequate acquisition and interpretation

2017 National Guideline Clearinghouse (partial archive)

15. Fatigue in multiple sclerosis: modafinil

disease pattern) at 8 weeks or 35 days respectively. No serious adverse effects of modafinil were reported in either RCT; however, common adverse effects, including gastrointestinal complaints and restlessness, were observed in both. The RCTs do not provide any evidence of the longer-term safety and efficacy of modafinil for treating fatigue in MS. Modafinil can cause serious adverse effects including psychiatric disorders, cardiovascular symptoms, and serious skin and multi-organ hypersensitivity (...) characteristics for modafinil warns that it can cause serious adverse effects including psychiatric disorders (such as suicidal ideation, mania and hallucinations), cardiovascular symptoms (such as hypertension and irregular heart beat), and serious skin and multi-organ hypersensitivity reactions (including Stevens–Johnson syndrome and toxic epidermal necrolysis). The European Medicines Agency (EMA) has completed a review of the safety and effectiveness of modafinil. The EMA's Committee for Medicinal Products

2013 National Institute for Health and Clinical Excellence - Advice

16. Parkinson's disease

features of Parkinson’s disease usually present unilaterally initially, but become bilateral as the disease progresses. Other causes of parkinsonism include drug-induced, cerebrovascular disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy. Parkinson's disease is a common condition in elderly people, with a prevalence of 1–2% in people older than 65 years of age. Typically, Parkinson's disease is slowly progressive, but the prognosis is variable. The mortality rate (...) and confirmed Parkinson's disease, including end-stage Parkinson's disease. This CKS topic does not cover the management of other causes of tremor or parkinsonism. There are separate CKS topics on symptoms and conditions that people with Parkinson's disease may experience, including , , , , , , , , , , , and . The target audience for this CKS topic is healthcare professionals working within the NHS in the UK, and providing first contact or primary healthcare. How up-to-date is this topic? How up-to-date

2018 NICE Clinical Knowledge Summaries

17. Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep-Wake Disorders: Advanced Sleep-Wake Phase Disorder (ASWPD), Delayed Sleep-Wake Phase Disorder (DSWPD), Non-24-Hour Sleep Wake Rhythm Disorder (N24SWD), and Irregular Sleep-W

-hour light-dark cycle and clock times. Thus, patients exhibit sleep-wake patterns that show a progressive delay (usually) or advance, depending upon the period length (tau) of their endogenous circadian rhythms. During a symptomatic period, the time of high sleep propensity gradually shifts, such that patients experience daytime hypersomnolence and nighttime insomnia. Most patients with N24SWD are totally blind, but this disorder also occurs among sighted individuals. In contrast to the other (...) ) is associated with a “black box” warning, due to increased mortality risks (approximately twofold higher than that associated with placebo-treated patients), mostly due to cardiovascular or infectious causes. 5.0 RECOMMENDATIONS FOR TREATMENTS OF INTRINSIC CRSWDs There were 8 different treatments, in addition to combination treatments, that were reviewed for the four intrinsic CRSWDs included in this guideline. The strengths of the recommendations, for those intrinsic CRSWD treatments that have

2015 American Academy of Sleep Medicine

18. Canadian guidelines on Parkinson?s disease

- S6Parkinson’s disease is characterized by a constellation of clinical manifestations, which include slowness of movement, rigidity, tremor and postural instability. Parkinson’s disease is a complex disorder that can be difficult to diagnose clinically, especially in the early stages. Diagnosis based on etiology is impractical because no single cause of PD has been identified. For instance, both genetic and environmental factors involved in PD pathogenesis have been identified. However, established monogenic (...) causes of PD account for only a minority of cases. Thus, currently the diagnosis of PD is based predominantly on the clinical features (Figure). Perhaps the most widely accepted clinical criteria for the diagnosis are those proposed by the UK Parkinson’s Disease Society Brain Bank. 1 C9 Parkinson’s disease should be suspected in people presenting with tremor, stiffness, slowness, balance problems and/or gait disorders. NICE Level D (GPP) There is no ideal way to define PD and distinguish it from

2012 CPG Infobase

19. A Clinical Perspective of Sleep and Andrological Health: Assessment, Treatment Considerations and Future Research. (PubMed)

A Clinical Perspective of Sleep and Andrological Health: Assessment, Treatment Considerations and Future Research. Sleep that is insufficient, misaligned or disrupted causes hypersomnolence and neuropsychological deficits, adversely affects cardiometabolic health and is increasingly recognized to impair other biological processes that lead to conditions important to men, such as hypogonadism, erectile dysfunction, and infertility.Literature review from 1970 to December 2018.High quality

2019 Journal of Clinical Endocrinology and Metabolism

20. Modafinil Versus Amphetamines for the Treatment of Narcolepsy Type 2 and Idiopathic Hypersomnia

recruiting First Posted : December 11, 2018 Last Update Posted : December 11, 2018 See Sponsor: Emory University Collaborator: American Academy of Sleep Medicine Information provided by (Responsible Party): Lynn Marie Trotti, Emory University Study Details Study Description Go to Brief Summary: For diseases that cause excessive daytime sleepiness (such as narcolepsy and idiopathic hypersomnia), there are several medications that can be used to treat sleepiness. However, it can be difficult to decide (...) modafinil or amphetamine salts -- no participant will receive placebo. This study will evaluate which medication works better to improve sleepiness. The researchers will also see which medication is better for other symptoms including difficulty waking up and difficulty thinking, as well as seeing which medication causes fewer side. Finally, this study will see if any information about patients (such as age or sleep study features) predicts responding better to one medication or the other. Condition

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>